Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to …
Post
-
-
Sanofi terminates Phase III CIPD trial due to low efficacy
Sanofi is terminating a Phase III chronic inflammatory demyelinating polyneuropathy (CIDP) trial of riliprubart after analysis showed the drug is …
-
Alpha Cognition announces top-line data in BEACON study for Alzheimer’s
Alpha Cognition has reported positive top line data from the BEACON real-world study assessing provider-reported outcomes for long-term care residents …
-
Windward Bio doses first patients in Phase II SIRIUS COPD trial
Harbour BioMed’s partner Windward Bio has dosed the first patients in the Phase II SIRIUS trial with HBM9378/WIN378 (SKB378), a fully …
-
ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering
This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and …
-
ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression
During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D) …
-
Study explores gaps in Europe’s steatotic liver disease response plans
The growing prevalence of metabolic dysfunction-associated steatotic liver disease and non-alcoholic steatotic hepatitis (MASLD/NASH) poses a growing public health risk, …
-
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III …
-
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a …
-
Alkeus doses first patient in Phase III NORTHSTAR trial
Alkeus Pharmaceuticals has dosed the first patient in its pivotal global Phase III NORTHSTAR study, investigating oral gildeuretinol (ALK-001) for …
-
Coya Therapeutics begins extension phase of ALSTARS trial for COYA 302
Coya Therapeutics has initiated the blinded extension phase of the ALSTARS trial, evaluating the safety and efficacy of COYA 302 …
-
ADA26: Kidney disease analysis given spotlight
At this year’s American Diabetes Association (ADA) congress, while obesity and diabetes treatments took the limelight, there were sessions focused …
-
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While Clinical …
-
ADA26: key obesity readouts from the conference
As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Clinical Trials Arena gives you …
-
Pfizer reports positive results from Phase IIb trial of berobenatide
Pfizer has reported detailed Phase IIb results for its investigational monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide, berobenatide (PF’3944), …
